7-methyl-6-azaspiro[3.4]octane hydrochloride | 1803586-35-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 7-methyl-6-azaspiro[3.4]octane hydrochloride
• 英文别名: 7-methyl-6-azaspiro[3.4]octane;hydrochloride
• CAS: 1803586-35-7
• 化学式: C₈H₁₅N*ClH
• mdl: MFCD28064021
• 分子量: 161.675
• InChiKey: AGHALSLLWBHGCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.35
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-噻吩磺酰氯 、 7-methyl-6-azaspiro[3.4]octane hydrochloride 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以68 %的产率得到7-methyl-6-((5-methylthiophen-2-yl)sulfonyl)-6-azaspiro[3.4]octane
  参考文献：
  名称：

  [EN] SPIROCYCLIC CAV2.3 ANTAGONISTS
  [FR] ANTAGONISTES DE CAV2.3 SPIROCYCLIQUES

  摘要：

  Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof wherein X1, R3, R4, a, b, p, q, r, L, and Ring A are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion channel Cav 2.3. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases modulated Cav 2.3, including neurodegenerative conditions such as Parkinson's disease, focal, drug-resistant forms of epilepsy, and other neurological disorders such as developmental and epileptic encephalopathies and Fragile X syndrome.

  公开号：

  WO2023094827A1
• 作为产物：
  描述：

  tert-butyl 7-methyl-6-azaspiro[3.4]octane-6-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 以100 %的产率得到7-methyl-6-azaspiro[3.4]octane hydrochloride
  参考文献：
  名称：

  [EN] SPIROCYCLIC CAV2.3 ANTAGONISTS
  [FR] ANTAGONISTES DE CAV2.3 SPIROCYCLIQUES

  摘要：

  Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof wherein X1, R3, R4, a, b, p, q, r, L, and Ring A are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion channel Cav 2.3. Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases modulated Cav 2.3, including neurodegenerative conditions such as Parkinson's disease, focal, drug-resistant forms of epilepsy, and other neurological disorders such as developmental and epileptic encephalopathies and Fragile X syndrome.

  公开号：

  WO2023094827A1